While the test is unlikely to be used as a diagnostic for the virus, it could be useful for identifying patients at high risk of developing severe disease.
The researchers found that levels of the marker, which has also been studied in diseases like MS and Alzheimer's, correlated with severity of traumatic brain injury.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
